Running title: RBM10 variants and RBM5 regulate alternative splicing of RBM10 v1 pre-mRNA. Abstract: RNA binding motif (RBM) proteins, RBM10v1, RBM10v2 and RBM5 have quite similar molecular structures with a high degree of the conserved domains. Alternative splicing of RBM10 pre-mRNA produces the two mRNA variants, RBM10v1 (exon 4-included) and RBM10v2 (exon 4-skipped). RBM10v1 has a 77 amino acids-domain coded by its exon 4, but RBM10v2 lacks it. I explored the alternative splicing of the RBM10 pre-mRNA by the above three RBMs in COS-7, lung adenocarcinoma A549 and differentiated mouse cardiomyocytes H9c2 cells. Firstly, COS-7 and A549 cells express both RBM10v1 and RBM10v2 mRNA variants in contrast to H9c2 cells which express RBM10v2 variant alone. Transfection experiments of RBM10v1, RBM10v2 or RBM5 were performed to examine the alternative splicing of RBM10v1 pre-mRNA in COS-7, A549 and H9c2 cells. The result showed that RBM10v1 includes, by itself, its own exon 4 of the pre-mRNA in contrast to RBM10v2 and RBM5 which exclude the exon 4. The inclusion of the exon 4 seems to be repressed in differentiated H9c2 cells.
Introduction
Nuclear speckles is enriched in the pre-mRNA splicing regulators and locate in the interchromatin regions of mammalian cells (1) . Splicing regulators are recruited to the active sites of transcription and the splicing machinery, spliceosomes. Stepwise assembly of various splicing regulators on the spliceosome is the most essential step. The initial step of splicing is binding of U1 snRNP with the pre-mRNA to form spliceosomal E complex (2) . Binding of U2 snRNP to the branch point region leads to the formation of spliceosomal A complex.
Preformed U4/U6/U5 tri-snRNP assembles with the precatalytic B complex and undergoes splicing of the target exon and intron. Proteomic studies of the complexes revealed the core protein composition and the interacting non-snRNPs which provided the molecular basis of inclusion or skipping of the alternative exons (3, 4) . The RNA binding proteins, HuR, PTB or TIA-1 antagonistically includes or skips the exon 6 of Fas receptor that encodes the transmembrane domain (5) (6) (7) . In addition, RBM5 skips the exon 6 of Fas pre-mRNA in HeLa cells (8) . Overexpressed RBM5 promotes distal alternative splice site pairing of the Fas pre-mRNA and thereby skips the alternative exon 6.
RBM5 modulates the expression of proapoptotic caspase 2L (9) and proapoptotic modulator Bax (10) . In addition, RBM5 increases Stat5b and BMP5 mRNAs but decreases CDK2 and Amplified in Breast cancer-1, proto-oncogene pim-1 (a caspase antagonist) (11) . In the breast carcinoma tissues, the expressions of two RBM10 variants and VEGF mRNAs significantly associate (12) and a similar association of RBM10v2, caspase 3 and proapoptotic Bax mRNAs is also reported (13) . However, neither knockdown nor overproduction of RBM10 does not effect on alternative splicing of caspase 2 and 3 pre-mRNAs in HeLa cells (14) .
Human RBM5 gene is frequently deleted in a variety of cancers (15) and RBM10 gene is also frequently mutated in lung adenocarcinomas (16) . RBM10v1 (930 AA), RBM10v2 (852AA) and RBM5 (815AA) have significant sequence similarity as reviewed previously (17) . So far, the functional relationship of the three RBMs has not been adequately clarified. The author has a hypothesis that the expression levels of the three RBMs possibly regulate alternative splicing of RBM10 pre-mRNA; accordingly, I explored a mechanism of alternative splicing of RBM10v1 pre-mRNA.
Materials and Methods

Cell lines and cell culture:
H9c2 rat cardiomyoblasts, A549 and COS-7 cells were used. COS-7 cells were provided from JCRB (Japanese Cancer Research Resources Bank, Tokyo, Japan). COS-7 cells are SV40-large T antigen transformed immortalized cell line. COS-7 cells rapidly grew in the present study. COS-7 cells were used as a high expresser of RBM10 variants and RBM5. A549 human lung cancer cells were provided by Dr. Qiau (Chubu University, Kasugai, Aichi, Japan). A549 cells grew more slowly than COS-7 cells. A549 cells were used as a low expresser of RBM5 as previously described (10, 18) . H9c2 rat cardiomyoblasts cell line was provided by Dr. Tatsumi (Nagoya University). H9c2 cells have a potential to differentiate to cardiomyocytes (19) . These cells were cultured in 6-well plates and passaged at a split ratio of 1:2 or 1:4. Each well contained 2 ml of Dolbeco's modified essential medium (DMEM) supplemented with 10% FCS, 1 mM glutamine and 60 g/ml kanamycine. The cells were grown until nearly full-confluent and the whole cell lysates were prepared (10 µg in SDS sample buffer) for Western blotting analysis of RBM10 and RBM5. The protein bands of RBM10V1, RBM10V2 or RBM5 were estimated by the image analysis software, Image-Pro plus (Media Cybernetics, MD. USA). Total RNA were prepared and used for RTPCR.
Antibodies and Western blot analysis:
Rabbit polyclonal anti-RBM10 against the GST fused N-terminal 43 kDa region (#1-166) of rat RBM10v2 was provided from Dr. Inoue (Osaka City University) (20) .
The anti-RBM10 antibody specifically recognized the RBM10v1 (130 kDa) and RBM10v2 (114kDa) (20) . The rabbit anti human RBM5 was provided by Dr. Oh (UCLA School of Medicine). The anti-RBM5 antibody was prepared against the COOH-terminal half of human RBM5 (amino acids 408-815 ) as described previously (21) .
The RBM10 and RBM5 proteins were successfully separated by SDS 8%-polyacrylamide gel electrophoresis based on their molecular sizes. The RBM proteins were identified with the primary rabbit anti-RBM10 or RBM5 antibody and the following secondary anti-rabbit IgG conjugated with Horse radish peroxidase (A6154; Sigma-Aldrich) or conjugated with alkaline phasphatase (T2180;Applied Biosystems).
Construction of expression vectors:
An expression vector of wild type human RBM5-GPF was provided by Dr. Valcárcel (University Pompeu Fabra, Barcelona, Spain). An expression vector of human wild type RBM10v1 cDNA (930 amino acids) was provided from Kazusa DNA Research Center (Kisarazu, Chiba, Japan). Expression vectors of wild type rat RBM10v2 cDNA (852 amino acids), human RBM10v1-GFP and rat RBM10v2-GFP were provided by Dr. Inoue (Osaka City University, Osaka, Japan). RBM10 cDNA was amplified by polymerase chain reaction with high fidelity KOD DNA polymerase (Toyobo Inc., Japan). The coding sequences of the vectors or their protein expression were confirmed by cDNA sequencing, restriction digestion or western blotting of the protein with the specific antibodies 2.4 siRNA knockdown of RBM10: 3'-Alexa Flour 647 -labeled RBM10 siRNA pairs; sense, r(ACAGAUGGAUGGAAGCCAAdTdT and antisense, r(UUGGCUUCCAUCCAUGGUG)dTdA were obtained from QIAGEN (QIAGEN Japan, Tokyo). COS-7 cells grown at 80%-confluency in a 4-well culture slide were transfected with 50 pmoles of the RBM10 siRNA (at final concentration of 100 nM) by using 5 µl of Hyperfect siRNA transfection reagent. After 48 hours, the whole cell lysates were prepared and the protein levels of RBM10 and RBM5 were analyzed as described in the previous section. COS-7 cells subconfluently grown in 6-well plates were transfected with control siRNA or RBM10 siRNA, incubated for 48 hours and then total RNA and the cell lysates were prepared as described previously.
Reverse transcription and PCR analysis:
Reverse transcription was performed from 1 µg of total RNA using Expand reverse transcriptase (Roche) and oligo dT or random hexamer oligonucleotides as a primer.
PCR was performed with GeneAmp PCR System 9700 (Applied Biosystems) using FastStart Taq DNA polymerase (Roche) as described in the manufacturer's instruction. The reaction mixture of PCR contained 1x PCR buffer, with or without 1x GC-RICH solution supplemented with 2 mM MgCl 2 , 0.2 mM of each dNTP, 0.5 µM of each forward and reverse primers and 2 Units of FastStart Taq DNA polymerase. cDNA was denatured at 95℃ for 6min and then amplified for 35 cycles using the following parameters: 95℃for 30 sec, 55℃ for 30 sec and 1min for 72℃, and at 72℃ for 7 min (final extension). The endogenous mRNAs of human RBM10v1, RBM10v2, RBM5 and β-actin were amplified. To monitor the efficiency and reproducibility of PCR amplification, glycerolaldehyde 3-phosphate dehydrogenase (GAPDH), caspase 2L or β-actin cDNA was amplified as a control as described by Nishio et.al., (22) .
For human RBM10v1 or RBM10v2, the forward primer RBM10A, 5'-AGGGCAAGCATGACTATGA-3' and reverse primer RBM10B, 5'-GTGGAGAGCTGGATGAAGG-3' were used as described by Martinez-Arribas et.al., (12) For human RBM5 (LUCA-15), the forward primer RBM5, LU15 (2) 5'-GACTACCGAGACTATGACAGT-3' and reverse RBM5, LU15(3) 5'-AGAGGACAGCTGCACAAATGC-3' were used as described by Rintala-Maki et.al (23) . Forward primer RBM5A, 5'-GACTACCGAGACTATGACAGT-3' and reverse primer RBM5B, 5'-AGAGGACAGCTGCACAAATGC-3' were used as another primer pair. For human VEGF, the forward primer, 5'-AGCTACTGCCATCCAATCGC-3' and reverse primer 5'-GGGCGAATCCAATTCC AAGAG-3' were used as described by Wong et.al (24) . For human caspase 2L (c-FLIP), the forward primer, 5'-GTTACCTGCACACCGAGTCACG-3' and reverse primer 5'-GCGTGGTTCTTTCCATCTTGTTGGTCA-3' were used according to Wang et.al (25) . For human GAPDH, the forward primer, 5'-AAGGCTGAGAACGGGAAGCTTGTCATCAAT-3' and reverse primer 5'-TTCCCGTCTAGCTCAGGGATGACCTTGCCC-3' were used as described by Nishio et.al., (22) . The amplified cDNA products were separated on agarose gels (1.8 % w/v) containing ethidium bromide (0.1 µg/ml).
The cDNA were visualized by UV-exposure and the cDNA images were captured by Olympus μ-7000 digital camera.
Results
RBM10 siRNA inhibits expression of the endogenous RBM10 mRNAs, but not RBM5: COS-7
cells were transfected with the RBM10-siRNA and cultured for 48 hours. The whole cell lysates or total RNAs were subjected to western blotting analysis of the RBM proteins or RTPCR of the RBM mRNAs, respectively.
The siRNA knockdown successfully down regulated the expression of RBM10v1 and RBM10v2, but not RBM5 as shown in Fig.1A . The results demonstrated that siRNA knockdown of RBM10 protein did not affect the expression of RBM5 mRNA. In addition, siRNA knockdown of the endogenous RBM5 under a similar condition was not successful due to a significantly high expression of RBM5 protein in COS-7 cells (data not shown).
Next I examined the effects of RBM10 siRNA and DOX on the alternative splicing of the Fas receptor mRNA as shown in Fig. 1B . The knockdown of RBM10 protein alone did not significantly alter the expression of two endogenous Fas receptor mRNA isoforms in COS-7 cells. Interestingly, the exposure to 1 or 2 µM DOX for 16 hours augmented the exon 6-skipped Fas 5-7 mRNA levels. In addition, the DOX-exposure decreased the RBM10 protein but not RBM5 (not shown). The DOX-exposed cells seemed to shift the equilibrium of the Fas isoform toward the exon 6-skiped Fas 5-7 mRNA due to the promotion of catalytic spliceosomes.
RBM10v1 mRNA includes entire Exon 4: encodes particular 77 amino acids domain. RBM10v1
mRNA has a particular exon 4 which encodes 77-AA domain (amino acids: #68-144), whereas RBM10v2 lacks the exon 4. So far the function of the 77-AA domain has not been fully investigated. The sequence alignments of the exon 4 and exon 9 of human RBM5, RBM10v1 or RBM10v2 are shown in supplement S1. The 77-AA domain locates at amino terminal to the two RNA biding motifs. The region of #131-144 is included in the RNA recognition motif 1 as predicted by Interpro protein sequence analysis and classification (EMBL-EBI data base).
The 77-AA domain consists of the unique amino acid sequences, an arginine-rich region: a 10 basic amino acids-cluster of QRRRRRRHRH (#79-88), an aspartic acid-rich region: HRHSPTGPPGFPRDGDYRDQDYR (#86-108) and a glutamic acid-rich region: a 13 acidic amino acids-cluster of EQGEEEEEEEDEEEEE (#110-125) and a part of RRM1 motif (IVMLRMLPQAATEDD). The conserved amino acids are highlighted in italic bold.
The basic and acidic residues are shown in underlined italic. The above-mentioned arginine and glutamic acid repeats, respectively exhibit strong positive and negative charge distribution which may suggest a potential biological role. Thereby, I termed the unique domain as RDE-rich domain of RBM10v1.
RBM5 has its own exon 4 which encodes 52 amino acids (#62-113) consisting of an aspartic acid-rich region The EGFP-expressed A549 cells expressed the proapoptotic caspase 2L mRNA, but a little caspase 2S mRNA (precursor of caspase 2L, not shown). Thereby the caspase 2L mRNA was not additively increased by the DOX treatment. The caspase 2L and the VEGF mRNAs were not affected by RBM10 variant expression, and thereby they were not alternatively spliced by RBM10 in A549 cells. Therefore, the caspase 2L mRNA was used as an internal control for the mRNA levels. It is known that RBM10 did not involve in caspase 2L pre-mRNA alternative splicing in HeLa cells also (14) . The short exposure of DOX to A549 cells for 6 hours did not alter the equilibrium of RBM10 mRNA variants. The tumor specific VEGF mRNAs were also not significantly affected by DOX. mRNA, a precursor of caspase 2L. In fact, the detection of a minor increase of the caspase 2L mRNA was difficult in the RBM5-GFP expressed A549 cells. mRNA levels nearly 1.7-fold and threefold, respectively, due to the additional production of the endogenous or exogenous RBM10v2 mRNA. When the exogenous RBM10v1-GFP was expressed in H9c2 cells, the endogenous RBM10v2 mRNA decreased to 43% of the control level. In addition, the expression of RBM10v1-GFP and RBM10v2-GFP did not affect the endogenous RBM5 mRNA levels (supplement Fig.S2-D) .
RBM5 skips exon 4 of
H9c2 cells express RBM10v2 alone but not RBM10v1: H9c2 cardiomyoblasts predominantly
Finally the present investigation demonstrated that the alternative splicing of RBM10 pre-mRNA is regulated by RBM10v1, RBM10v2 and RBM5 in COS-7 cells, A549, and H9c2 rat cardiomyoblasts. cardiomyoblasts expressed RBM10v2 alone. This finding suggests a differential regulatory mechanism to balance or shift the equilibrium between RBM10v1 and RBM10v2 in the highly proliferative cells or differentiated cells. Hence, I explored the switching between the two RBM10 variants in COS-7 cells (high expresser of RBMs), A549 cells (moderate expresser of RBMs) and H9c2 cells (low expresser of RBMs). The cells were transiently transfected with pRBM10v1-GFP or pRBM10v2-GFP construct. The exogenous expression of RBM10v1-GFP predominantly increased the RBM10v1 mRNA but significantly impaired the endogenous RBM10v2 mRNA. The expression of RBM10v2-GFP also increased the RBM10v2 mRNA but impaired the endogenous RBM10v1 mRNA. The result indicates that RBM10v1 specifically recognizes its own exon 4 of RBM10v1 pre-mRNA and facilitates its inclusion, whereas RBM10v2 skips it. Some other splicing regulator can skip the alternative exon of its own pre-mRNAs. One example is polypyrimidine tract binding protein (PTB) which has an autoregulatory activity. Overexpression of PTB activates the skipping of exon 11 from its own pre-mRNA, yielding a premature termination codon containing isoform that are targeted to nonsense-mediate decay (26) . In addition, RBM4 skips the exon 11 of PTB pre-mRNA to down-regulate PTB, as myoblasts commit to terminal differentiation (27) .
Discussion
Alternative splicing mechanism of RBM10 pre-mRNA by RBM10v1, RBM10v2 and RBM5:
RBM10v1 and RBM5 mRNA has its own exon 4 which encodes 77 and 52 amino acids, respectively, whereas RBM10v2 lacks the entire exon 4 as shown in supplement S1. Exon 4 of RBM5 encodes an aspartic acid-rich region and a part of RRM1, but lacks the arginine-rich (DSYEASPGSETQRRRRRR) and glutamic acid rich Interestingly V354E-mutation in the RRM2 disrupts the function of RBM10 and does not inhibit proliferation of A549 lung adenocarcinoma, because the mutated RBM10 does not promote skipping of exon 9 of the gene NUMB (28, 29) . Recently, the solution structure of the RBM5 RRM2 core domain was determined and its flexible RNA binding properties were revealed (30) . The RBM5 RRM2 can preferentially bind both CU and GA rich sequences (5'-CUCUUC-3' or 5'-GAGAAG-3'). Taken together it is likely that the flexible RNA binding properties of RBM5 and RBM10 and in addition a unique RDE-rich domain of RBM10v1 seem to involve with alternative splicing of RBM10 pre-mRNA.
Then, I explored the expression of the RBM10v2 mRNA (exon 4-skipped RBM10) and its promotion by the exogenously expressed RBM5 in A549 cells (moderate expresser of RBM5) and H9c2 cells (expresser of RBM10v2 and RBM5). Interestingly the RBM5 expression predominantly decreased the endogenous RBM10v1 mRNA in A549 cells but increased the endogenous RBM10v2 mRNA in A549 cells or H9c2 cells. The ratios of v1/v2 and v1/RBM5 were decreased in the RBM5-GFP-transdected, but not in the none-treated and pEGFP-transfected cells as shown in supplement Fig S2E. The results suggest that among the high or low expressers of RBMs, the activities of RBM10v1, RBM10v2 or RBM5 may set a unique balance of the RBM10v1 and RBM10v2 proteins.
RBM5 plays a key role as an alternative splicing regulator of the proapoptotic factors as described previously (9, 10) . A molecular mechanism of alternative splicing of Fas receptor pre-mRNA is based on the pre-spliceosomal assembly of RBM5 (8) . RBM5 directly interacts with exon 6 of the Fas pre-mRNA on the pre-spliceosome and does not affect the association of U1 and U2 snRNPs to the adjacent splice sites. Finally RBM5 inhibits the incorporation of the U4/U6-U5 tri-snRNP complex on the introns flanking the Fas-exon 6, and promotes the pairing of U1 and U2 at the distal splice sites, contributing to skipping the exon 6.
Sixty amino acids-OCRE domain of RBM10v1 (#561-621) and RBM5 (#451-511) has the OCRE sequence motif that contains a unique tyrosine-rich sequence (31) (32) (33) . The OCRE domain is highly conserved among human RBM10v1, RBM10v2 and RBM5 (with the positive identities of 100 %). Mutation of the conserved aromatic residues of the OCRE-motif impaired the skipping of Fas exon 6 (31) . Thereby the OCRE-motif is required for alternative splicing after targeting the RBM10v1 pre-mRNA.
The present investigation indicates that exon 4 skipping of RBM10v1 is similar in mechanism of exon 6 skipping of Fas by RBM5. It is intriguing to speculate that RBM10v2 and RBM5 interact with the RBM10v1 
Correlation of RBM10 variant and other RBMs in human cancer cells or tumor tissues of the
advanced grade: Differential RTPCR analysis of the X-chromosome RBM gene expressions was performed in human breast carcinoma tissues, which indicated that the expressions of RBM10v2 associate with high proliferation of the tumors and those of RBM10v1 and RBM10v2 are interdependent (12) . Notably, in the breast carcinoma tissues, a significant inverse correlation of the mRNA levels between the breast cancer metastasis suppressor-1 (BRMS1) and RBM10v1 was reported (34) .
Correlated expressions between RBM5 and RBM10v1 or those between RBM6 and RBM10v2 are highly significant in the breast tumor tissues (35) . The positive correlation between RBM6 and RBM10v2 mRNA increases in relation to the advanced tumor grade, increased tumor size and loss of progesterone receptor. The two RBM mRNA expressions are highly significant in the Grade 3 ductal carcinoma. RBM5, RBM10v1 and HER2 protein expression levels are elevated in the tumor tissues. The consistent strong positive correlations of the RBMs may suggest their functional interrelation or antagonism. RBM5 modulates the expression of proapoptotic factor Bax, enhances caspase-3 activity and causes apoptosis in A549 lung cancer cells (10) . In addition, RBM10v2, Bax and caspase 3 mRNAs are coexpressed in the breast tumor tissues (13) . The statistically significant correlation of the above three proteins suggest that the both of RBM5 and RBM10v2 may involve in the splicing of the Bax pre-mRNA. So far, molecular mechanism of the interdependency or correlation among the RBMs has not been clarified.
In the present study, I found the inverse interdependency of RBM10 variants and the positive correlation of RBM5 and RBM10v2 mRNA. It is intriguing to speculate that the inverse interdependency of the RBM10 variants may be associated with accompanying alternative splicing of RBM10 pre-mRNA by RBM10 variant itself and RBM5. The primarily generated RBM10v1 will increase its own RBM10v1 mRNA. In contrast, RBM5 has a potential for generating the RBM10v2 variant. The secondary generated RBM10v2 will increase its own mRNA variant and the translation product, RBM10v2 that facilitates its own mRNA production further.
Therefore, significantly high expression of RBM10v1 may reflect its antagonistic function to RBM10v2 and RBM5. Finally, RBM10v1 variant may be dominantly expressed in a variety of cancers that deleted RBM5 gene.
A previous investigation revealed a nonsense mutation (at 1235G>A) or a flame shift mutation (at c1893_1894insA) of human RBM10 gene (36) . The mutated RBM10 gene seems to produce a truncated or RBM10v2. The identical residues in the all sequences are red in the highlighted yellow columns. The consensus residue derived from a block of similar residues at a given position among the two RBM is blue in the highlighted light blue columns. The consensus residue derived from the occurrence of greater than 50% of a single residue at a given position is black in the highlighted green columns. The unique residues of RBM10v1 exon 4 are black in the highlighted yellow columns. The non-similar residues are black. The dotted lines show the lack of the corresponding residues. A double headed arrow above the alignment shows a part of RRM1 or RRM2 coded by exon 4 or exon 10, respectively.
Supplement S2
Alignments of RRM1 and RRM2 motifs of RBM10v1, RBM10v2, RBM5 or RBM6. The consensus residues derived from a completely conserved residue at a given position among all the RRM motifs are red in the highlighted yellow columns. The consensus residue derived from a block of similar residues at a given position among the RRM motifs is blue in the highlighted light blue columns. The consensus residue derived from the occurrence of greater than 50% of a single residue at a given position among the motifs is black in the highlighted green columns.
The residue weakly similar to consensus residue at given position is green.
The non-similar residues are black. The identity or positive identity of each RRM motif is indicated. 
